CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » Genitourinary Cancer » Testicular Cancer

ONCOLOGY. Vol. 10 No. 9
 

Commentary (Foster): Prognostic Factors in Low-Stage Nonseminomatous Testicular Cancer

The Moul/Heidenreich Article Reviewed

By Richard S. Foster, MD1 | September 1, 1996
1Indiana University, Medical Center, Indianapolis, Indiana

The paper by Drs. Moul and Heidenreich provides a very nice review of prognostic factors for metastasis in patients with clinical stage I nonseminoma. Risk-adapted management--ie, the management of patients at low risk for metastasis by surveillance and patients at high risk for metastasis by retroperitoneal lymph node dissection (RPLND)--is very reasonable, and we are now at a point where a paradigm can be developed to accurately classify clinical stage I patients as either low or high risk and manage them accordingly.

The paper describes nerve-sparing RPLND as a "major abdominal procedure." Although post-chemotherapy RPLND is associated with significant morbidity, nerve-sparing RPLND is not.[1] I also disagree with the authors' statement that vascular invasion and percentage of embryonal carcinoma have "extreme clinical utility," since these factors have not been verified prospectively in a consecutive group of patients. As is well known, retrospective studies in selected patients do not necessarily generate a paradigm that is proven to be clinically valid prospectively in unselected patients.

(MORE: Prognostic Factors in Low-Stage Nonseminomatous Testicular Cancer)

The authors' analysis of histologic and molecular factors is very well done and well referenced. However, they should have included in the clinical prognostic factors a section on lymph node diameter on CT scan as a predictor of pathologic stage.[2] The experience from Indiana would suggest that pathologic stage varies continuously with measured lymph node diameter on CT scan.

Need for a Prospective, Multi-institutional Study

Many of the studies described by Moul and Heidenreich were carried out retrospectively in selected patients. Furthermore, the paper accurately describes the potential problems with interobserver variability relative to histologic and immunohistochemical parameters. What is needed is a multi-institutional study of these parameters that is done prospectively in unselected patients. Such a study has the potential to validate one or more of the paradigms described in this paper and would allow us to determine whether or not interobserver variability can be minimized. Hopefully, such a study will be undertaken by the cooperative groups

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

This Expert Perspective refers to the following article

Prognostic Factors in Low-Stage Nonseminomatous Testicular Cancer



Judd W. Moul, MD, FACS, and Axel Heidenreich, MD


1. Baniel J, Foster RS, Rowland RG, et al: Complications of primary retroperitoneal lymph node dissection. J Urol 152:424-427, 1994.

2. Leibovitch I, Foster RS, Kopecky KK, et al: Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using criteria of retroperitoneal lymph nodes. J Urol 154:1759-1763, 1995.


 
RELATED CONTENT

ASCO: Post-Surgery Surveillance Found Safe in Seminoma
June 17, 2013
Genomics Studies Identify Testicular Cancer Risk Variants
May 17, 2013
Testicular Mass Discovered in 28-Year-Old Patient
February 25, 2013
Smoking Marijuana Linked to Increased Risk of Testicular Cancer
September 12, 2012
A 30-Year-Old Man Presents With Swelling of the Right Testicle
March 26, 2012
 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
  • ASCO: Yoga Reduces Insomnia in Breast Cancer Patients Treated With Hormone Therapy
  • Physical Activity Across the Cancer Continuum
  • Exercise After Cancer Diagnosis: Time to Get Moving
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • ASCO: No Benefit From Avastin in Newly Diagnosed Glioblastoma
Click here to subscribe to our newsletter


CancerNetwork on Facebook
 
SEARCHMEDICA SEARCH RESULTS

Find peer-reviewed literature and websites for practicing medical professionals

CME on Testicular Cancer
Evidence on Testicular Cancer
Guidelines on Testicular Cancer
Patient Education on Testicular Cancer
Clinical Trials on Testicular Cancer
Practical Articles on Testicular Cancer
Research and Reviews on Testicular Cancer
All "Testicular Cancer" results

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy